KLS-13019

KLS-13019 is an orally active GPR55 receptor antagonist and a structural analogue of cannabidiol (CBD) . It can prevent and reverse chemotherapy-induced peripheral neuropathy (CIPN) in a dose-dependent manner in rats[1].

Product Specifications

CAS Number

[1801243-39-9]

UNSPSC

12352005

Target

GPR55

Type

Reference compound

Related Pathways

GPCR/G Protein; Neuronal Signaling

Field of Research

Neurological Disease

Assay Protocol

https://www.medchemexpress.com/kls-13019.html

Smiles

CC([C@@H]1CCC(C)=C[C@H]1C2=C(C=C(C=C2O)CC3CN(C3)C(C)=O)O)=C

Molecular Formula

C22H29NO3

Molecular Weight

355.47

References & Citations

[1]Ippolito MJ, et al. KLS-13019, a novel structural analogue of cannabidiol (CBD) and GPR55receptor antagonist, Prevents and Reverses Chemotherapy-Induced Peripheral Neuropathy (CIPN) in Rats. J Pharmacol Exp Ther. 2024 Aug 22:JPET-AR-2024-002190.